Small-cap biotechnology firm, Genfit (NASDAQ:GNFT), is climbing 2% in pre-market trading. After hitting a recent lull, is Genfit stock about to break out?
Let’s check this out.
Genfit StockThe French biotech company uplisted to the NASDAQ exchange in late March. Since then, it has hit highs of $25.65 and lows of $20.14—the latter only hit several days ago. Everything has been going well for the firm, so what caused the recent drop?
The issue lies with Genfit’s lead candidate drug called elafibranor. However, it is also the potential in this drug ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.